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Background: Cysteine-rich 61 (Cyr61), a member of the CCN protein family, possesses diverse functionality in
cellular processes such as adhesion, migration, proliferation, and survival. Cyr61 can also function as an oncogene or
a tumour suppressor, depending on the origin of the cancer. Only a few studies have reported Cyr61 expression in
colorectal cancer. In this study, we assessed the Cyr61 expression in 251 colorectal cancers with clinical follow up.
Methods: We examined Cyr61 expression in 6 colorectal cancer cell lines (HT29, Colo205, Lovo, HCT116, SW480,
SW620) and 20 sets of paired normal and colorectal cancer tissues by western blot. To validate the association of
Cyr61 expression with clinicopathological parameters, we assessed Cyr61 expression using tissue microarray analysis
of primary colorectal cancer by immunohistochemical analysis.
Results: We verified that all of the cancer cell lines expressed Cyr61; 2 cell lines (HT29 and Colo205) demonstrated
Cyr61 expression to a slight extent, while 4 cell lines (Lovo, HCT116, SW480, SW620) demonstrated greater Cyr61
expression than HT29 and Colo205 cell lines. Among the 20 cases of paired normal and tumour tissues, greater
Cyr61 expression was observed in 16 (80%) tumour tissues than in normal tissues. Furthermore, 157 out of 251
cases (62.5%) of colorectal cancer examined in this study displayed strong Cyr61 expression. Cyr61 expression was
found to be associated with pN (p = 0.018). Moreover, Cyr61 expression was associated with statistically significant
cancer-specific mortality (p = 0.029). The duration of survival was significantly lesser in patients with Cyr61 high
expression than in patients with Cyr61 low expression (p = 0.001). These results suggest that Cyr61 expression plays
several important roles in carcinogenesis and may also be a good prognostic marker for colorectal cancer.
Conclusions: Our data confirmed that Cyr61 was expressed in colorectal cancers and the expression was correlated
with worse prognosis of colorectal cancers.
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Cysteine-rich 61 (Cyr61) is a member of the CCN
(Cyr61/CTGF/Nov) protein family, which consists of
Cyr61 (CCN1); connective tissue growth factor (CTGF/
CCN2), nephroblastoma-overexpressed (Nov/CCN3); and
Wnt-induced secreted proteins 1, 2 and 3 (Wisp-1/CCN4,
Wisp-2/CCN5, and Wisp-3/CCN6, respectively). These
CCN proteins are involved in multiple functional path-
ways, including mitogenesis, cellular adhesion, migration,
cell survival, differentiation, angiogenesis, and wound* Correspondence: ssurge@schmc.ac.kr
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reproduction in any medium, provided the orhealing [1]. Among the various CCN proteins, a majority
of studies have been conducted on Cyr61 or CCN1 with
reference to cancer. Cyr61 is expressed by all types of vas-
cular cells, participating in such diverse cellular processes
as adhesion, migration, proliferation, and survival [2,3].
Notably, an important role for Cyr61 in the processes of
angiogenesis and vascularization is being seen. Neovascu-
larization of tumours is one of the most important func-
tions of tumour growth factors; thus, Cyr61 participates in
tumour progression by neovascularization. In addition to
angiogenesis, CCN1 can promote cancer cell proliferation,
invasion, survival, and metastasis [4,5]. Overexpression of
Cyr61 is associated with the growth and progression of
breast cancer [6], ovarian cancer [7], gastric cancer [8,9],td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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to function as a tumour suppressor in prostate cancer [12],
uterine leiomyoma [13], non-small cell lung cancer [14,15],
and endometrial cancer [16]. Cyr61 may exert different, even
opposing, functions in tumorigenesis, depending on the
cell types.
Colorectal cancer (CRC) is one of the commonest can-
cers worldwide and was ranked second in 2010 for can-
cer incidence in South Korea [17]. At least 3 primary
molecular pathways involved in the progression of CRC
have been identified, including the prevalent chromo-
somal instability (CIN) pathway (identified in up to 80%
of cases), the CpG island methylator phenotype (CIMP)
pathway, and microsatellite instability (MSI), resulting
from the DNA mismatch repair (MMR) gene [18]. How-
ever, the precise mechanism underlying colorectal car-
cinogenesis remains unclear.
More recently, studies have focused primarily on mo-
lecular biomarkers to indicate progression of a disease
or susceptibility of the disease to a given treatment [19].
Cyr61 plays important roles in carcinogenesis, either
as an oncogene or as a tumour suppressor gene, depend-
ing on the cancer type. The purpose of our study is to
clarify whether Cyr61 functions as an oncogene or as an
anti-oncogene in CRC and to determine whether there is
a correlation between Cyr61 expression and clinicopatho-
logical parameters, including prognosis. We also verified
that Cyr61 is a relevant biomarker of CRC progression.
Methods
Patients and samples
We obtained formalin-fixed, paraffin-embedded specimens
from 251 patients with primary CRC. All patients with
cancer underwent surgery from 2002 to 2007. Clinico-
pathological data including age, sex, lymph node metasta-
sis, American Joint Committee on Cancer (AJCC) TNM
classification, and tumour differentiation were recorded
(Table 1). Our work was approved by the Institutional
Review Board of the College of Medicine, Soonchunhyang
University.
Western blot assay
Cancer cells were washed with PBS and lysed using the
Pro-Prep protein extraction kit (Intron, Seoul, South Korea)
at 4°C overnight. The supernatant containing protein was
collected after centrifugation. Protein concentrations were
determined using a BCA Protein Assay Kit (Thermo Scien-
tific, Waltham, MA, USA). Cell lysate samples (30 μg) were
loaded onto 10% SDS-PAGE, separated at 110 V for 2 h,
and transferred to a PVDF membrane with the Trans-Blot
Turbo system (Bio-Rad Laboratories, Hercules, CA, USA).
The membrane was blocked for 1 h in blocking buffer con-
sisting of 5% non-fat skim milk/1X TBS-T (Tris-buffered
saline with 0.1% Tween 20) for 1 h at room temperature,followed by incubation with primary monoclonal anti-
Cyr61 antibody at 4°C overnight, diluted in 1X TBS-T
(1:1000; R&D Systems, Minneapolis, MN, USA). After a
5 times wash with TBS-T, the membrane was incubated
with a goat anti-mouse secondary antibody in 1X TBS-T
(1:80,000 dilution; Sigma Chemicals, St. Louis, MO, USA)
for 1 h at room temperature. The membranes were
washed 4–5 times in 1X TBS-T for 1 h. The signal was
detected using an enhanced chemiluminescence kit (ECM
solution; Advansta, Menlo Park, CA, USA) and Molecular
Imager ChemiDoc XRS + System (Bio-Rad Laboratories).
Beta-actin was used as the loading control. The relative
Cyr61 expression was measured by Image Densitometer
(Bio-Rad, Laboratories) with beta-actin normalization. The
relative Cyr61 expressions in tumour tissues compared
to those in normal tissues were calculated by tumour/
normal ratio.
Tissue microarray
Tissue microarrays (TMAs) were assembled from 10% neu-
tral buffered formalin-fixed paraffin-embedded tissues by
using a 2-mm-diameter punch (UNITMA, Unitech Science,
Seoul, South Korea). Tissue microarrays were constructed
by obtaining primarily duplicate cores of formalin-fixed
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the cores in an arrayed recipient paraffin block. A TMA
block contains 60 cores from 30 samples. Samples obtained
from the same tumour were staggered in the array, and a
map was created for later identification of the identity of
the individual cores.
Immunohistochemical analysis
Four-micrometer-thick sections were sliced onto Silane
Coated Micro Slides (Muto Pure Chemicals Corp., Tokyo,
Japan) and incubated at 60°C for 2 h. The slides were then
deparaffinized by application of xylene and incubation
(5 min ×3) at room temperature. Sections were hydrated
by application of graded alcohol, and endogenous peroxid-
ase activity was quenched by incubating the sections in
0.3% H2O2 in methanol for 30 min at room temperature.
After washing the slides in phosphate-buffered saline (PBS;
5 min × 2), antigen retrieval was performed by heating the
slides in citrate buffer (0.01M, pH 6.0) using a microwave
in a pressure cooker for 15 min. After heating, the samples
were allowed to cool off for 2 h at room temperature
followed by washing with PBS (3 min × 2). Immunohisto-
chemical (IHC) analysis was performed using Cyr61 pri-
mary antibody (Abcam, Cambridge, UK) with incubation
for 2 h at room temperature with an UltraVision Quanto
Detection System HRP DAB (Lab Vision Corp., Fremont,
CA, USA) according to the manufacturer’s instructions.
IHC data analysis
The Cyr61-stained tissue cores were examined by 2 inde-
pendent observers (CJK and DJJ), and a consensus score
was determined for each specimen. A positive reaction was
scored into 4 grades, according to the intensity of the stain-
ing: 0, 1+, 2+, and 3+. The percentages of Cyr61-positive
cells were also scored into 4 categories: 0 (0%), 1 (1–33%),
2 (34–66%), and 3 (67–100%). The final score, calculated
as the product of the intensity score multiplied by the per-
centage score, was classified as follows: 0 for negative; 1–3
for weak; 4–6 for moderate; and 7–9 for strong. Samples
with a final score ≤3 were grouped together as Cyr61 ex-
pression negative while those with a score ≥4 were grouped
together as Cyr61 expression positive.
Statistical analysis
The data were analysed using commercially available
software (SPSS 18.0; SPSS; Chicago, IL, USA). The clin-
ical and pathologic factors that were evaluated included
pT (1, 2, 3, and 4), pN (0, 1, and 2), vascular invasion,
lymphatic invasion, and TNM stage classification (I, II,
III, and IV). For investigating the relationships between
Cyr61 expression and the clinicopathological factors, chi-
square tests were performed. A p value, two-sided test was
also performed; values less than 0.05 were considered
statistically significant for all analyses. The clinical andpathologic variables and Cyr61 expression were consid-
ered for survival analysis using the Kaplan-Meier method.
The statistical significance was set at a p value less than
0.05 and assessed by the log-rank test. Hazard ratio (HR)
and 95% confidence interval (95% CI) were estimated
from Cox proportional hazard models. For final multivari-
able Cox regression models, all covariates were controlled.
Results
Cyr61 protein expression in CRC cell lines and
normal-cancer paired CRC tissues by western blot
We examined Cyr61 expression in 6 CRC cell lines by
Western blot. All 6 cancer cell lines expressed Cyr61; 2
cell lines (HT29 and Colo205) demonstrated slight Cyr61
expression, while 4 cell lines (Lovo, HCT116, SW480,
SW620) demonstrated greater Cyr61 expression than the
HT29 and Colo205 cell lines (Figure 1A). Furthermore,
we examined Cyr61 expression in 20 sets of paired normal
and CRC tissues by western blot. Among the 20 normal
and tumour tissue pairs, greater Cyr61 expression was ob-
served in tumour tissues versus normal tissues in 16 cases
(80%) (Figure 1B).
Cyr61 expression in CRC tissue by Immunohistochemistry
Cyr61 was not expressed in most normal tissues. In tumour
tissue, Cyr61 was expressed with a wide range of intensity,
ranging from negative to severe staining (Figure 2A-D).
Among the 251 cases, a positive result for IHC Cyr61 stain-
ing was observed in 157 samples (62.2%) (Table 2). The
frequency of Cyr61 expression was 5.1%, 12.7%, 66.9%,
and 15.3% for pT stages 1, 2, 3, and 4, respectively. Posi-
tive Cyr61 expression was significantly related with the
pT stage (p = 0.021). The frequencies of Cyr61 expression
for pN stages 0, 1, and 2 were 46.5%, 35.7% and 17.8%,
respectively; these results were statistically significant
(p = 0.006). Furthermore, the frequencies of Cyr61 ex-
pression were 13.4% and 16.6% when examining vascular
invasion and lymphatic invasion, respectively; however,
these results were not statistically significant (p = 0.700
and p = 0.563, respectively). However, the frequencies of
Cyt61 expression for TNM stages I, II, III, and IV were
10.8%, 32.5%, 50.3%, and 6.4% respectively (p = 0.001); the
results were statistically significant (Table 2). Age, sex, pT
stage, venous invasion, lymphatic invasion, tumour differ-
entiation were not related with prognosis by univariate
and multivariate Cox hazard regression analysis. pN stage
1 was found to be associated with prognosis in multi-
variate analysis (HR, 2.02; 95% CI, 1.04–3.94; p = 0.038).
Additionally, pN stage 2 was associated with prognosis
both in univariate analysis (HR, 2.90; 95% CI, 1.44–5.83;
p = 0.003) and in multivariate analysis (HR, 2.53; 95%
CI, 1.20–5.32; p = 0.015) (Table 3). Moreover, strong Cyr61
expression was found to be prognostic factor both in uni-
variate analysis (HR, 2.56; 95% CI, 1.29–5.08; p = 0.007)
Figure 1 Western blot analysis of Cyr61 expression. (A) All of the cancer cell lines expressed Cyr61. (B) Representative 10 pairs of normal and
tumour tissue. Greater Cyr61 expressions were observed in tumour tissues than in normal tissues. The relative Cyr61 expression was measured by
densitometry with beta-actin normalization (*). The relative Cyr61 expressions in tumour tissues compared to those in normal tissues were
calculated by tumour/normal ratio (T/N).
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p = 0.029), as determined by Cox hazard regression analysis
(Table 3). The duration of survival was significantly lesser
in patients with Cyr61 high expression than in those Cyr61
low expression (p = 0.001) (Figure 3).
Discussion
Cyr61 is a multifunctional matricellular protein that per-
forms various essential roles in cardiovascular develop-
ment during embryogenesis, as well as regulates would
healing, inflammation, and fibrogenesis [20]. Aberrant
Cyr61 expression is associated with the development of
various cancers and diseases linked to chronic inflamma-
tion. Cyr61 promotes diverse, and sometimes opposing,Figure 2 Cyr61 expressions in tissues by immunohistochemistry. (A) N
expression. (B) Some colorectal cancer shows negative Cyr61 expression. (C
expressed in severe degree in the carcinoma.cellular responses. Structurally, CYR61 protein consists of
an N-terminal secretory peptide followed by 4 conserved
domains with sequence homologies to insulin-like growth
factor-binding protein (IGFBP), von Willebrand factor C
repeat (VWC), thrombospondin type I repeat (TSR), and a
carboxyl-terminal (CT) domain that contains a cysteine
knot motif [1]. A nonconserved central hinge region bi-
sects the protein into 2 halves that bind to distinct recep-
tors and induce diverse and disparate cellular responses.
Early studies on Cyr61 protein showed that it is tightly as-
sociated with the extracellular matrix (ECM) [21] and sup-
ports cellular adhesion by direct binding to integrin
receptors [22,23]. Cyr61 functions as a matricellular pro-
tein rather than a growth factor to induce cell proliferationormal glands in the colorectum demonstrate negative Cyr61
) Cyr61 is expressed in mild degree in the carcinoma. (D) Cyr61 is
Table 2 Comparison of clinicopathological factors and Cyr61 expression
Clincopathological factors Cyr61 Total (%) p
Positive N = 157 (%) Negative N = 94 (%)
Age, years, mean (SD) 62.2 (12.2) 65.2 (11.5) 63.3 (12.0) 0.061
Sex 0.296
Male 88 (56.1) 59 (62.8) 147 (58.6)
Female 69 (43.9) 35 (37.2) 104 (41.4)
pT stage 0.021
1 8 (5.1) 2 (2.1) 10 (4.0)
2 20 (12.7) 21 (22.3) 41 (16.3)
3 105 (66.9) 66 (70.2) 171 (68.1)
4 24 (15.3) 5 (5.3) 29 (11.6)
pN stage 0.006
0 73 (46.5) 63 (67.0) 136 (54.2)
1 56 (35.7) 19 (20.2) 75 (29.9)
2 28 (17.8) 12 (12.8) 40 (15.9)
Vascular invasion 0.700
0 136 (86.6) 83 (88.3) 219 (87.3)
1 21 (13.4) 11 (11.7) 32 (12.7)
Lymphatic invasion 0.563
0 131 (83.4) 81 (86.2) 212 (84.5)
1 26 (16.6) 13 (13.8) 39 (15.5)
TNM stage 0.001
I 17 (10.8) 18 (19.1) 35 (13.9)
II 51 (32.5) 47 (50.0) 98 (39.0)
III 79 (50.3) 26 (27.7) 105 (41.8)
IV 10 (6.4) 3 (3.2) 13 (5.2)
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tivities; for example, it promotes cellular survival, yet trig-
gers cellular apoptosis; it enhances cell proliferation, yet
induces cell-cycle arrest; and it promotes tumour growth,
yet suppresses tumorigenesis in varying contexts, depend-
ing on the cell type. These disparate Cyr61 activities are
attributed to its interaction with distinct integrins and
heparan sulphate proteoglycans (HSPGs) on the surface
of both endothelial cells and stromal fibroblasts. These
Cyr61 activities stimulate both epithelial-mesenchymal
transition and invasion of certain cancer cells [4,5,25].
Moreover, Cyr61 induces angiogenesis, which is essential
for the supply of oxygen and nutrients to nourish tumour
growth [26]. In addition to angiogenesis, Cyr61 promotes
cancer cell proliferation, invasion, survival, and metastasis
[4,5,27]. Significant correlation between Cyr61expression
and tumour stage, tumour size, lymph node positivity, and
poor prognosis have been reported in several types of can-
cers, including breast cancer [3,28-31], prostate cancer
[32], glioma [33], gastric cancer [9], and oral squamous
cell carcinoma [34]. However, only a few studies have beenperformed on the relationship between Cyr61 expression
and CRC initiation and/or progression. A single report by
Ladwa et al. [35] was retrieved in a worldwide search of
journals published in English; they reported that Cyr61
was expressed in 82% (23/28) of CRCs examined and that
Cyr61 expression was associated with more advanced clin-
ical stages. In our study, all 7 CRC cell lines expressed
Cyr61 with varying intensities. Five cell lines exhibited
relatively strong expression levels of Cyr61, while 2 cells
lines expressed lower levels of Cyr61. Furthermore, among
the 20 sets of paired normal and cancer tissues, the tumour
tissues exhibited stronger Cyr61 expression than paired
normal tissues in 16 cases (80%). This result suggests that
Cyr61 plays several roles in colorectal carcinogenesis, a hy-
pothesis supported by the Cyr61 expression levels observed
by IHC analysis in clinical samples. Among 251 cases of
CRCs examined in this study, 157 cases (62.5%) displayed
strong Cyr61 expression. The prevalence of Cyr61 expres-
sion in our study is lower than that reported by Landwa
et al. [35]. This discrepancy could be attributed to either
sample size or different primary antibodies used in the
Figure 3 Survival curves from the time of diagnosis for colorectal cancer patients by Cyr61 expression. The duration of survival was
significantly lesser in patients with Cyr61 high expression than in those with Cyr61 low expression.
Table 3 Cox hazards regression analysis of the clinicopathological factors
Clinicopathological factors
Univariate analysis Multivariate analysis
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
Age 1.01 (0.99–1.03) 0.514 1.00 (0.98–1.03) 0.858
Sex (0 =male, 1 = female) 1.03 (0.60–1.77) 0.917 1.20 (0.66–2.20) 0.548
pT stage
1 1.00 1.00
2 1.09 (0.24–5.03) 0.916 0.93 (0.18–4.86) 0.927
3 1.13 (0.27–4.70) 0.864 0.99 (0.19–4.88) 0.967
4 3.44 (0.68–17.78) 0.140 2.15 (0.34–13.86) 0.419
pN stage
0 1.00 1.00
1 1.83 (0.99–3.40) 0.056 2.02 (1.04–3.94) 0.038
2 2.90 (1.44–5.83) 0.003 2.53 (1.20–5.32) 0.015
Venous invasion 1.00 (0.45–2.21) 0.991 0.67 (0.23–1.96) 0.463
Lymphatic invasion 1.84 (0.98–3.44) 0.057 1.97 (0.79–4.90) 0.143
Differentiation
Well 1.00 1.00
Moderate 0.70 (0.36–1.40) 0.298 0.61 (0.28–1.30) 0.198
Poor 0.86 (0.24–3.08) 0.817 0.75 (0.18–3.09) 0.692
Cyr61 Expression
Negative 1.00 1.00
Negative to mild expression 0.89 (0.48–1.67) 0.721 0.86 (0.44–1.70) 0.662
Moderate to severe expression 2.56 (1.29–5.08) 0.007 2.31 (1.09–4.89) 0.029
CI, confidence interval.
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in the progression of CRC in this study, as Cyr61 expres-
sion levels were higher in more advanced pT, pN, and
TNM stages than in less advanced stages. Strong Cyr61 ex-
pression was associated with poor prognosis (p = 0.029), as
determined by Cox hazard regression analysis. The survival
analysis, performed using the Kaplan-Meier method, dem-
onstrated that survival was significantly lower in patients
with Cyr61 high expression than in patients with Cyr61
low expression (log rank test, p = 0.002). This study reports
the first survival analysis involving the IHC evaluation of
Cyr61 expression in CRC. The results of this study support
the hypothesis that Cyr61 promotes cancer cell prolifera-
tion, invasion, and metastasis [4,5,26,27]. However, several
lines of evidence support the hypothesis that Cyr61 can
suppress tumour growth functioning as an antioncogene.
Cyr61 inhibits NSCLC cell proliferation by upregulating
p53, p21, and p130/Rb gene expression [15], suggesting
that Cyr61 may induce senescence through a p53-/pRb-
dependent pathway [36]. Likewise, overexpression of Cyr61
inhibits the proliferation of hepatocellular carcinoma cells,
in part through p53 action [37]. Furthermore, overexpres-
sion of Cyr61 in endometrial carcinoma cells has been re-
ported to decrease cell growth and increase apoptosis [16].
Additionally, Cyr61 expression in melanoma cells reduces
tumour growth and metastasis and concomitantly in-
creases apoptosis in tumours [38]. Thus, the role of Cyr61
in tumorigenesis may be dependent on cell type and con-
text. In conclusion, the results of this study suggest that
Cyr61 expression plays an important role in the carcino-
genesis and progression of CRC, as well as in predicting
patient survival. Further investigations may validate the po-
tential utility of Cyr61 as a biomarker or therapeutic target
against CRC.
Conclusions
Our data suggest that Cyr61 expression in colorectal
cancers is associated with patients survival and may thus
serve as prognostic marker.
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